Unicycive Therapeutics
UNCY
15 hedge funds and large institutions have $1.38M invested in Unicycive Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
25% more funds holding
Funds holding: 12 → 15 (+3)
4.12% less ownership
Funds ownership: 11.18% → 7.06% (-4.1%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
85% less capital inflows, than outflows
Capital inflows: $230K | Capital outflows: $1.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$150K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$31.3K |
| 3 |
Centiva Capital
New York
|
+$23.7K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$22.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.51M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$45.5K |
| 3 |
Squarepoint
New York
|
-$24.1K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$2.11K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2 |
UNCY Hedge Fund Activity: Q2 2023 in Review
15 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q2 2023, worth a combined $1.38M — down 61% from $3.54M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new UNCY positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $150K. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.51M sold.
- 15 institutional investors held Unicycive Therapeutics (UNCY) as of Q2 2023, up from 12 in Q1 2023.
- Funds reported $1.38M of Unicycive Therapeutics stock for Q2 2023, down 61% quarter-over-quarter.
- 5 funds opened new Unicycive Therapeutics positions in Q2 2023 and 2 closed out, a net change of +3 holders.
- The largest Unicycive Therapeutics buyer in Q2 2023 was Goldman Sachs, an estimated $150K added.
- The largest Unicycive Therapeutics seller in Q2 2023 was Balyasny Asset Management, an estimated $1.51M sold.
Based on aggregated 13F filings for Q2 2023.